Fig. 4
From: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Patient response to treatment. a Median time to response for patients with measurable disease (investigator assessment). b Duration of response. c Probability of response in patients with measurable disease
